Singapore markets open in 8 hours 25 minutes

Clovis Oncology, Inc. (CLVS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.3050+0.1150 (+2.74%)
As of 12:34PM EDT. Market open.
Currency in USD

Valuation measures

Market cap (intra-day) 5496.14M
Enterprise value 3938.57M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/sales (ttm)2.66
Price/book (mrq)N/A
Enterprise value/revenue 35.98
Enterprise value/EBITDA 7-3.43

Trading information

Stock price history

Beta (5Y monthly) 1.76
52-week change 3-26.88%
S&P500 52-week change 330.30%
52-week high 311.1000
52-week low 34.0600
50-day moving average 34.5117
200-day moving average 35.2363

Share statistics

Avg vol (3-month) 32.89M
Avg vol (10-day) 32.16M
Shares outstanding 5118.41M
Implied shares outstanding 6N/A
Float 8116.49M
% held by insiders 11.64%
% held by institutions 149.89%
Shares short (29 Sep 2021) 426.61M
Short ratio (29 Sep 2021) 48.06
Short % of float (29 Sep 2021) 422.99%
Short % of shares outstanding (29 Sep 2021) 422.48%
Shares short (prior month 30 Aug 2021) 427.17M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021

Profitability

Profit margin -197.75%
Operating margin (ttm)-159.88%

Management effectiveness

Return on assets (ttm)-26.13%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)156.94M
Revenue per share (ttm)1.58
Quarterly revenue growth (yoy)-7.70%
Gross profit (ttm)128.39M
EBITDA -242.37M
Net income avi to common (ttm)-310.36M
Diluted EPS (ttm)-3.1220
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)230.2M
Total cash per share (mrq)1.94
Total debt (mrq)672.63M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.70
Book value per share (mrq)-1.75

Cash flow statement

Operating cash flow (ttm)-219.02M
Levered free cash flow (ttm)-134.91M